Coexpression of c-Met and Notch-1 correlates with poor prognosis in resected non-small-cell lung cancer

Tumor Biology

Volumn 36, Issue 9, 2015, Pages 7053-7059

  Wang, Ximing ^a   Song, Na ^a   Zhang, Ye ^a   Cai, Ying ^a   Liu, Yunpeng ^a   Qu, Xiujuan ^a   Li, Zhi ^a   Li, Danni ^a   Hou, Kezuo ^a   Kang, Jian ^a   Hu, Xuejun ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

c Met; Immunohistochemistry staining; Notch 1; NSCLC; Prognosis

Indexed keywords

NOTCH1 RECEPTOR; SCATTER FACTOR RECEPTOR; NOTCH1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SMOKING; TUMOR DIFFERENTIATION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; AGED; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, NOTCH1;

EID: 84947061991     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3404-4     Document Type: Article

References (24)

1. Matsuguma H, Nakahara R, Iqarashi S, Ishikawa Y, Suzuki H, Miyazawa N, et al. Pathologic stage I non-small cell lung cancer with high levels of preoperative serum carcinoembryonic antigen: clinicopathologic characteristics and prognosis. J Thorac Cardiovasc Surg. 2008;135(1):44–9. doi:10.1016/j.jtcvs.2007.09.032.
2. Ozeki N, Fukui T, Taniguchi T, Usami N, Kawaguchi K, Ito S, et al. Significance of serum carcinoembryonic antigen level during the follow-up of patients with completely resected non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014;45(4):687–92. doi:10.1093/ejcts/ezt424.
3. Gumustekin M, Kargi A, Bulut G, Gozukizil A, Ulukus C, Oztop I, et al. HGF/c-Met overexpressions, but not met mutation, correlates with progression of non-small cell lung cancer. Pathol Oncol Res. 2012;18(2):209–18. doi:10.1007/s12253-011-9430-7.
4. Ozasa H, Oguri T, Maeno K, Takakuwa O, Kunii E, Yagi Y, et al. Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells. Cancer Sci. 2014;105(8):1032–9. doi:10.1111/cas.12447.
5. Tanaka A, Sueoka-Aragane N, Nakamura T, Takeda Y, Mitsuoka M, Yamasaki F, et al. Co-existence of positive MET FISH status with EGFR mutations signifies poor prognosis in lung adenocarcinoma patients. Lung Cancer. 2012;75(1):89–94. doi:10.1016/j.lungcan.2011.06.004.
6. Guo B, Cen H, Tan X, Liu W, Ke Q. Prognostic value of MET gene copy number and protein expression in patients with surgically resected non-small cell lung cancer: a meta-analysis of published literatures. PLoS One. 2014;9(6):e99399. doi:10.1371/journal.pone.0099399. eCollection 2014.
7. Chen G, Qiu Y, Sun L, Yu M, Wang W, Xiao W, et al. The jagged-2/notch-1/hes-1 pathway is involved in intestinal epithelium regeneration after intestinal ischemia-reperfusion injury. PLoS One. 2013;8(10):e76274. doi:10.1371/journal.pone.0076274. eCollection 2013.
8. Yao L, Kan EM, Kaur C, Dheen ST, Hao A, Lu J, et al. Notch-1 signaling regulates microglia activation via NF-kappa B pathway after hypoxic exposure in vivo and in vitro. PLoS One. 2013;8(11):e78439. doi:10.1371/journal.pone.0078439. eCollection 2013.
9. Li L, Zhao F, Lu J, Li T, Yang H, Wu C, et al. Notch-1 signaling promotes the malignant features of human breast cancer through NF-kappa B activation. PLoS One. 2014;9(4):e95912. doi:10.1371/journal.pone.0095912. eCollection 2014.
10. Eliasz S, Liang S, Chen Y, De Marco MA, Machek O, Skucha S, et al. Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene. 2010;29(17):2488–98. doi:10.1038/onc.2010.7.
11. Chen Y, De Marco MA, Graziani I, Gazdar AF, Strack PR, Miele L, et al. Oxygen concentration determines the biological effects of NOTCH-1 signaling in adenocarcinoma of the lung. Cancer Res. 2007;67:7954–9. doi:10.1158/0008-5472.CAN-07-1229.
12. Williams CK, Li JL, Murga M, Harris AL, Tosato G. Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. Blood. 2006;107(3):931–9. doi:10.1182/blood-2005-03-1000.
13. Donnem T, Andersen S, AI-Shibli K, Al-Saad S, Busund LT, Bremnes RM. Prognostic impact of Notch ligands and receptors in non-small cell lung cancer: coexpression of Notch-1 and vascular endothelial growth factor-A predicts poor survival. Cancer. 2010;116(24):5676–85. doi:10.1002/cncr.25551.
14. Apostolou P, Toloudi M, Ioannou E, Kourtidou E, Chatziioannou M, Kopic A, et al. Study of the interaction among Notch pathway receptors, correlation with stemness, as well as their interaction with CD44, dipeptidyl peptidase-IV, hepatocyte growth factor receptor and the SETMAR transferase, in colon cancer stem cells. J Recept Signal Transduct Res. 2013;33(6):353–8. doi:10.3109/10799893.2013.828072.
15. Guessous F, Zhang Y, Kofman A, Catania A, Li Y, Schiff D, et al. microRNA-34a is tumor suppressive in brain tumors and glioma stem cells. Cell Cycle. 2010;9(6):1031–6.
16. Yun J, Pannuti A, Espinoza I, Zhu H, Hicks C, Zhu X, et al. Crosstalk between PKC-alpha and Notch-4 in endocrine-resistant breast cancer cells. Oncogenesis. 2013;2:e60. doi:10.1038/oncsis.2013.26.
17. Breindel JL, Haskins JW, Cowell EP, Zhao M, Nguyen DX, Stern DF. EGF receptor activates MET through MAPK to enhance non-small cell lung carcinoma invasion and brain metastasis. Cancer Res. 2013;73(16):5053–65. doi:10.1158/0008-5472.CAN-12-3775.
18. Yang L, Li J, Ran L, Pan F, Zhao X, Ding Z, et al. Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells. J Gastrointest Surg. 2011;15(6):942–57. doi:10.1007/s11605-011-1504-z.
19. Kumai T, Matsuda Y, Oikawa K, Aoki N, Kimura S, Harabuchi Y, et al. EGFR inhibitors augment antitumour helper T-cell responses of HER family-specific immunotherapy. Br J Cancer. 2013;109(8):2155–66. doi:10.1038/bjc.2013.577.
20. Li H, Hu H, Wang R, Pan Y, Wang L, Li Y, et al. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. Onco Targets Ther. 2014;7:513–24. doi:10.2147/OTT.S60122. eCollection 2014.
21. Farrell J, Kelly C, Rauch J, Kida K, García-Muñoz A, Monsefi N, et al. HGF induces epithelial-to-mesenchymal transition by modulating the mammalian hippo/MST2 and ISG15 pathways. J Proteome Res. 2014;13(6):2874–86. doi:10.1021/pr5000285.
22. Huang J, Song H, Liu B, Yu B, Wang R, Chen L. Expression of Notch-1 and its clinical significance in different histological subtypes of human lung adenocarcinoma. J Exp Clin Cancer Res: CR. 2013;32:84. doi:10.1186/1756-9966-32-84.
23. Xie M, Zhang L, He CS, Xu F, Liu JL, Hu ZH, et al. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells. J Cell Biochem. 2012;113(5):1501–13. doi:10.1002/jcb.24019.
24. Stella MC, Trusolino L, Pennacchietti S, Comoglio PM. Negative feedback regulation of Met-dependent invasive growth by Notch. Mol Cell Biol. 2005;25(10):3982–96. doi:10.1128/MCB.25.10.3982-3996.2005.